Onzima Ventures PLC Result of General Meeting (9241D)
May 02 2017 - 8:06AM
UK Regulatory
TIDMONZ
RNS Number : 9241D
Onzima Ventures PLC
02 May 2017
02 May 2017
Onzima Ventures plc (to be re-named N4 Pharma Plc)
(the "Company")
Result of General Meeting, Directorate Changes, Share
Re-organisation, Change of Name and Website address and Voting
Rights
Result of General Meeting
The Company is pleased to announce that all resolutions put to
Shareholders at the General Meeting held earlier today were duly
passed and therefore completion of the acquisition of N4 Pharma
Limited is expected to take place on 3 May 2017.
Directorate Changes
Following the passing of the resolutions as set out above, the
Company announces, each with effect upon Admission, the
resignations of Gavin Burnell, Chief Executive, and Professor
Humayun Mughal, Non-Executive Director, as directors of the Company
and the appointments of David Templeton, Non-Executive Chairman,
Nigel Theobald, Chief Executive, and Paul Titley, Executive
Director, as directors of the Company. Further details on the newly
appointed directors are set out in the Appendix below.
Share Re-organisation
At the General Meeting, Shareholders approved the Share
Re-organisation which is expected to take place after close of
business on the Record Date, being 2 May 2017. Fractional
entitlements resulting from the Share Re-organisation will be sold
for the benefit of Shareholders other than amounts of less than
GBP5.00 which the Company will retain for its own benefit.
Change of Name and Website Address
At the General Meeting, Shareholders also approved the change of
the Company's name from Onzima Ventures Plc to N4 Pharma Plc. The
change of name will be effective once Companies House has issued a
certificate of incorporation on change of name which is expected to
occur by Admission. The Company's AIM symbol will change to N4P
with effect from 8.00am on 3 May 2017.
Following the change of the Company's name becoming effective,
its website address, which will include the information required by
AIM Rule 26, will be www.n4pharma.com.
Voting Rights
Application has been made for the Enlarged Share Capital to be
admitted to trading on AIM. It is expected that restoration of
trading on AIM in the Existing Ordinary Shares and Admission will
become effective and that dealings in the Enlarged Share Capital
will commence at 8.00am on 3 May 2017.
Following completion of the Company's Share Re-organisation and
Admission, the Enlarged Share Capital will comprise 71,714,285
Ordinary Shares. Each Ordinary Share has one voting right. No
Ordinary Shares are held in treasury. Accordingly, the total number
of voting rights will be 71,714,285.
The above figure may be used by Shareholders as the denominator
for the calculation by which they will determine if they are
required to notify their interest in, or a change to their interest
in, N4 Pharma plc under the FCA's Disclosure Guidance and
Transparency Rules.
Defined terms used in this announcement shall have the same
meaning as in the Company's admission document published on 13
April 2017, copies of which are available on the Company's
website.
Enquiries:
N4 Pharma
Nigel Theobald, Via Alma PR
CEO
Stockdale Securities
Tom Griffiths Tel: +44(0)207 601
6100
Beaufort Securities
Elliot Hance Tel: +44(0)207 382
8300
Alma PR
Josh Royston Tel: +44(0)778 090
Robyn Fisher 1979
Tel: +44(0)754 070
6191
Appendix
The following information is disclosed pursuant to Schedule Two
paragraph (g) of the AIM Rules for Companies. The newly appointed
Directors, as mentioned above, hold or have held the following
directorships or have been partners in the following partnerships
within the past five years:
Name Current Directorships/Partnerships Past Directorships/Partnerships
---------------- ----------------------------------- --------------------------------
David Templeton None DT Pharmacology Consultancy
Limited
---------------- ----------------------------------- --------------------------------
Nigel Theobald Askalane Limited Oxford Nutra Limited
Lytegro Limited Oxford Pharmascience
Medherant Limited Group Plc
N4 Pharma Limited Oxford Pharmascience
Limited
---------------- ----------------------------------- --------------------------------
Paul Titley Critical Pharmaceuticals Aesica Formulation Development
Limited
Keswick Community Asset
Company
Keswick Museum and Art
Gallery
N4 Pharma Limited
---------------- ----------------------------------- --------------------------------
In addition, as at the date of this announcement, Nigel Theobald
holds 29,893,963 Existing Ordinary Shares, representing
approximately 16.1 per cent of the Existing Ordinary Share
Capital.
There is no other information that is required to be disclosed
pursuant to Schedule 2 paragraph (g) of the AIM Rules for
Companies.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ROMLLFIVEFIFIID
(END) Dow Jones Newswires
May 02, 2017 09:06 ET (13:06 GMT)
Onzima Ventures (LSE:ONZ)
Historical Stock Chart
From Apr 2024 to May 2024
Onzima Ventures (LSE:ONZ)
Historical Stock Chart
From May 2023 to May 2024